Home Cart Sign in  
Chemical Structure| 848344-36-5 Chemical Structure| 848344-36-5

Structure of Bentamapimod
CAS No.: 848344-36-5

Chemical Structure| 848344-36-5
Product Citations

Alternative Products

Product Details of Bentamapimod

CAS No. :848344-36-5
Formula : C25H23N5O2S
M.W : 457.55
SMILES Code : N#CC(C1=NC(OCC2=CC=C(C=C2)CN3CCOCC3)=NC=C1)C4=NC5=CC=CC=C5S4
Synonyms :
AS 602801
MDL No. :MFCD08272350
InChI Key :XCPPIJCBCWUBNT-UHFFFAOYSA-N
Pubchem ID :10195250

Safety of Bentamapimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H332
Precautionary Statements:P261-P280

Related Pathways of Bentamapimod

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK1

    JNK1, IC50:80 nM

  • JNK2

    JNK2, IC50:90 nM

  • JNK3

    JNK3, IC50:230 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
GS-Y01 glioblastoma stem cells 7.5 μM 3 days AS602801 showed cytotoxicity against patient-derived glioblastoma stem cells PMC5053629
A2780 CSLCs ovarian cancer stem cells 7.5 μM 3 days AS602801 showed cytotoxicity against ovarian cancer stem cells, with sensitivity comparable to the original cell lines PMC5053629
A549 CSLCs lung cancer stem cells 7.5 μM 3 days AS602801 showed cytotoxicity against lung cancer stem cells, with sensitivity comparable to the original cell lines PMC5053629
PANC-1 CSLCs pancreatic cancer stem cells 7.5 μM 3 days AS602801 showed cytotoxicity against pancreatic cancer stem cells, with sensitivity comparable to the original cell lines PMC5053629
A2780 ovarian cancer cells 7.5 μM 3 days AS602801 induced cell death and reduced viable cell numbers, showing selective cytotoxicity against ovarian cancer cells PMC5053629
A549 lung cancer cells 7.5 μM 3 days AS602801 induced cell death and reduced viable cell numbers, showing selective cytotoxicity against lung cancer cells PMC5053629
PANC-1 pancreatic cancer cells 7.5 μM 3 days AS602801 induced cell death and reduced viable cell numbers, showing selective cytotoxicity against pancreatic cancer cells PMC5053629
IMR90 normal human fibroblasts 10 μM 3 days Evaluate the toxicity of AS602801 on non-neoplastic cells, showing no significant toxicity at 10 μM PMC5053629
Human endometrial organ cultures (from women with endometriosis) 5 or 15 μM 72 h To evaluate the effect of AS602801 on MMP-3 release. Results showed that AS602801 alone or in combination with MPA suppressed MMP-3 production, while PR or MPA alone failed. PMC5933194
Human endometrial organ cultures (from healthy women) 5 or 15 μM 72 h To evaluate the effect of AS602801 on MMP-3 release. Results showed that AS602801 alone or in combination with MPA reduced MMP-3 release. PMC5933194
Human vestibular schwannoma cells 2, 20, 50 µM 24 h AS602801 significantly reduced proliferation and increased apoptosis in human vestibular schwannoma cells. PMC10193498

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/cAJcl-nu/nu mice Subcutaneous xenograft model Intraperitoneal injection 40 mg/kg Once daily for 10 consecutive days Systemic administration of AS602801 reduced tumor-initiating cancer stem cells in xenograft tumors without affecting mouse health PMC5053629
Nude mice Xenograft model of endometriosis Oral 10 or 30 mg/kg Once daily for 30 days To evaluate the effect of AS602801 on regression of endometriotic lesions. Results showed that 30 mg/kg AS602801 caused 29% regression of lesions. PMC5933194
Nude mice Human vestibular schwannoma xenograft model Oral gavage 60 mg/kg Twice daily for 65 days AS602801 reduced tumor volume and cell proliferation but did not significantly increase apoptosis. PMC10193498

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.93mL

2.19mL

1.09mL

21.86mL

4.37mL

2.19mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories